EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Dyslipidemia and statin use in people with HIV-1 infection: beyond the lipid-lowering effect

Gianluca Gazzaniga, Marco Ridolfi, Alessandro Lazzaro, Tommaso Brogi, Pasquale Pignatelli, Daniele Pastori, Ivano Mezzaroma

Nutrition, Metabolism and Cardiovascular Diseases · 2025-10 · 35 (10) · 104110

DOI: 10.1016/j.numecd.2025.104110 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nutrition, Metabolism and Cardiovascular Diseases, 2025-10. Verfasst von Gianluca Gazzaniga und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery and Surgical Specialty Paride Stefanini, Sapienza University of Rome, Rome, Italy; Department of Medical Biotechnology …. Hauptthemen laut MEDLINE: Dyslipidemias, HIV Infections, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Anti-HIV Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sapienza University of Rome.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: Advances in antiretroviral therapy have transformed HIV-1 infection into a chronic condition, enabling people living with HIV-1 (PWH) to achieve life expectancies comparable to those of the uninfected population. Consequently, a range of co-morbidities, particularly an increased incidence of cardiovascular events, has becoming more evident. Among these, dyslipidemia stands out as a significant risk factor with a multifactorial pathogenesis. The aim of this narrative review is to highlight the multifactorial origins of dyslipidemia in PWH, to provide an overview of drug interactions between statins and antiretroviral therapy, and examine the unique anti-inflammatory and immunomodulatory properties of statins in this context. DATA SYNTHESIS: Some studies indicate a reduction of mortality and cardiovascular risk in PWH treated with statins. However, the benefit of statin therapy is variable and seems to be dependent on HIV-1 length exposure and type of antiretroviral drugs and seems to be lower in individuals without comorbidities or additional risk factors. Statins are often underdosed for the perceived risk of drug interactions. Beyond their lipid-lowering effects, statins exert additional benefits, including anti-inflammatory and immunomodulatory actions on vascular tissues, monocyte-macrophages, and lymphocytes. These effects have sparked interest in their potential applications beyond dyslipidemia treatment. CONCLUSIONS: Statins may provide a clinical benefit in PWH by lowering LDL cholesterol and modulating immunity and inflammation. However, there is a clinical need for HIV-1-specific LDL cholesterol targets given the excess cardiovascular risk in this population, as well as for the identification of high-risk subgroups that may benefit most from statin treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DyslipidemiasHIV InfectionsHydroxymethylglutaryl-CoA Reductase InhibitorsAnti-HIV AgentsHIV-1Anti-Inflammatory AgentsCardiovascular DiseasesLipidsHumansDrug InteractionsTreatment OutcomeBiomarkersRisk AssessmentHeart Disease Risk FactorsImmunomodulating AgentsInflammation MediatorsRisk Factors

Stichwörter der Autor:innen

Antiretroviral therapyChronic inflammationDyslipidemiaHIV-1Immune activationStatins

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsAnti-HIV AgentsBiomarkersAnti-Inflammatory AgentsLipidsImmunomodulating AgentsInflammation Mediators

Autor:innen und Institutionen

  • Department of General Surgery and Surgical Specialty Paride Stefanini, Sapienza University of Rome, Rome, Italy; Department of Medical Biotechnology and Translational Medicine, Postgraduate School of Clinical Pharmacolo…
  • Department of Internal Medicine, Endocrine-Metabolic Sciences and Infectious Diseases, AOU Policlinico Umberto I, Rome, Italy.
  • Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
  • Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy; IRCCS Neuromed, Località Camerelle, Pozzilli, Isernia, Italy. Electronic address: daniele.pastori…
  • Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.

Förderung

  • Sapienza University of Rome

Zitieren

APA

Gazzaniga, G., Ridolfi, M., Lazzaro, A., Brogi, T., Pignatelli, P., Pastori, D., & Mezzaroma, I. (2025). Dyslipidemia and statin use in people with HIV-1 infection: beyond the lipid-lowering effect. Nutrition, Metabolism and Cardiovascular Diseases, 35(10), 104110. https://doi.org/10.1016/j.numecd.2025.104110

Vancouver

Gazzaniga G, Ridolfi M, Lazzaro A, Brogi T, Pignatelli P, Pastori D, et al. Dyslipidemia and statin use in people with HIV-1 infection: beyond the lipid-lowering effect. Nutrition, Metabolism and Cardiovascular Diseases. 2025;35(10):104110. doi:10.1016/j.numecd.2025.104110

BibTeX
@article{Gazzaniga2025,
  author = {Gazzaniga, Gianluca and Ridolfi, Marco and Lazzaro, Alessandro and Brogi, Tommaso and Pignatelli, Pasquale and Pastori, Daniele and Mezzaroma, Ivano},
  title = {Dyslipidemia and statin use in people with HIV-1 infection: beyond the lipid-lowering effect},
  journal = {Nutrition, Metabolism and Cardiovascular Diseases},
  year = {2025},
  volume = {35},
  number = {10},
  pages = {104110},
  doi = {10.1016/j.numecd.2025.104110}
}
Kostenlos starten →